
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. has seen a significant increase in advertising expenses, which rose by 34% year-over-year to a total of $100 million in 2023, demonstrating the company's commitment to driving awareness and procedural growth. The company anticipates continued spending in both direct-to-consumer advertising and expects a rise in average selling prices (ASPs) beginning in calendar year 2026, supported by improved reimbursement strategies that could enhance volume and profitability. Despite a year-to-date decline of 26% in stock price, shares have surged approximately 86% since the third quarter earnings per share announcement, indicating strong investor confidence fueled by better-than-expected performance and positive outlooks.
Bears say
Inspire Medical Systems Inc. is facing a negative outlook primarily due to a decline in advertising expenditures, with 2024 ad spend projected to decrease by 5% year-over-year, indicating potential challenges in market penetration. The launch of the new Inspire 5 product has encountered unforeseen difficulties, prompting management to lower revenue and EPS forecasts, which negatively impacts the company’s stock valuation. Additionally, reduced operating expenditures, particularly in research and development as well as selling and administrative expenses, suggest a significant scaling back of growth initiatives, further compounding concerns about future revenue generation.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares